Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Geneuro SA
GNROCurrent price
0.078 EUR
-0.0004 EUR (-0.51%)
Last closed
0.078 EUR
Company
www.geneuro.com
ISIN
CH0308403085
Sector
Healthcare
Industry
Biotechnology
Exchange
Euronext Paris
Capitalization
2 360 824 EUR
Yield for 12 month
-92.88 %
1Y
3Y
5Y
10Y
15Y
GNRO
GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family; treats type 1 diabetes; and treats chronic inflammatory demyelinating polyneuropathy. It also developing GNK301. In addition, It has cooperative research and development agreements with The National Institute of Neurological Disorders and Stroke to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis; and Academic centers to develop inflammatory psychosis, as well as a research collaboration agreement with International Center for Infectiology Research; and with Northwestern University for human endogenous retrovirus W envelope protein (HERV-W ENV) in long-haul COVID patients. The company was incorporated in 2006 and is headquartered in Plan-les-Ouates, Switzerland. Address: 3 chemin du PrE-Fleuri, Plan-les-Ouates, Switzerland, 1228
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
6.59 EURP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
-296 655 EUR
Last Year
-291 304 EUR
Current Quarter
-147 822 EUR
Last Quarter
-148 833 EUR
Key Figures GNRO
1 year
3 years
5 years
10 years
EBITDA
-14 456 850 EUR
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-100.64 %
PEG Ratio
–
Return On Equity TTM
-386.76 %
Wall Street Target Price
6.59 EUR
Revenue TTM
116 219 EUR
Book Value
-0.56 EUR
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
7 535 632 EUR
Earnings per share
-0.6 EUR
Diluted Eps TTM
-0.6 EUR
Most Recent Quarter
IV 2023
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics GNRO
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History GNRO
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation GNRO
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
518.9367
Price Sales TTM
382.751
Enterprise Value EBITDA
-6.0936
Price Book MRQ
24.1463
Financials GNRO
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators GNRO
For 52 weeks
0.056 EUR
2.37 EUR
50 Day MA
0.077 EUR
Shares Short Prior Month
–
200 Day MA
0.85 EUR
Short Ratio
–
Shares Short
–
Short Percent
–
BeatStart